Trondheim, Norway

Per Arne Aas

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Per Arne Aas: Innovator in Oligopeptidic Compounds

Introduction

Per Arne Aas is a notable inventor based in Trondheim, Norway. He has made significant contributions to the field of biochemistry, particularly through his work on oligopeptidic compounds. With a total of 3 patents, Aas has focused on developing methods for treating disorders by inhibiting cell growth.

Latest Patents

Aas's latest patents include innovative methods involving oligopeptidic compounds. One patent discloses a method of treatment for conditions where it is desirable to inhibit cell growth. This method involves administering an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA). The compound features a specific PCNA interacting motif and comprises 9-70 subunits along with at least one signal sequence. Another patent elaborates on similar oligopeptidic compounds and their applications in cytostatic therapy and inflammation treatment.

Career Highlights

Throughout his career, Aas has worked with various companies, including Apim Therapeutics AS and Lybe Scientific AS. His work has been instrumental in advancing the understanding and application of oligopeptidic compounds in medical treatments.

Collaborations

Aas has collaborated with notable colleagues such as Marit Otterlei and Emadoldin Feyzi. These collaborations have contributed to the development of his innovative patents and research.

Conclusion

Per Arne Aas is a distinguished inventor whose work on oligopeptidic compounds has the potential to impact medical treatments significantly. His contributions to the field are marked by his innovative patents and collaborations with other experts.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…